Endocrinology, Vol 134, 783-789, Copyright © 1994 by Endocrine Society

ARTICLES

The D2 dopamine receptor mediates inhibition of growth in GH4ZR7 cells: involvement of protein kinase-C epsilon

SE Senogles
Department of Biochemistry, University of Tennessee, Memphis 38163.

The D2 dopamine agonist, bromocriptine, has been used as treatment for human PRL-secreting pituitary adenomas. The result of bromocriptine treatment is often a substantial reduction of tumor mass, suggesting that the dopamine agonist is acting as an antiproliferative agent. This action can be observed with a clonal pituitary tumor cell line. The agonist activation of the D2 dopamine receptor inhibits the growth of GH4ZR7 cells, a GH4C1 cell line stably transfected with the cDNA encoding the short form of the D2 dopamine receptor. This effect of dopamine was not sensitive to overnight treatment with 100 ng/ml pertussis toxin. Treatment of GH4ZR7 cells with the phorbol ester 4 beta-phorbol 12,13-didecanoate resulted in the loss of dopaminergic inhibition of growth, whereas treatment with 4 alpha-phorbol 12,13- didecanoate had no effect. Inhibitors of protein kinase-C (PKC), such as staurosporine and H7, also blocked the effect of dopamine. Down- regulation of cellular PKC by phorbol ester treatment resulted in a complete loss of dopaminergic inhibition of growth. Long term treatment of GH4ZR7 cells with TRH results in a specific down-regulation of the epsilon form of PKC and abolished the ability of dopamine to inhibit growth. These results suggest that PKC epsilon is involved in mediating the antiproliferative effects of dopamine. This mediation of growth appears to be through a novel signaling pathway for the D2 dopamine receptor.

This article has been cited by other articles:

				C.-Y. Lin, M. G. Varma, A. Joubel, S. Madabushi, O. Lichtarge, and D. L. Barber Conserved Motifs in Somatostatin, D2-dopamine, and alpha 2B-Adrenergic Receptors for Inhibiting the Na-H Exchanger, NHE1 J. Biol. Chem., April 18, 2003; 278(17): 15128 - 15135. [Abstract] [Full Text] [PDF]

				G. Liu, M. H. Ghahremani, B. Banihashemi, and P. R. Albert Diacylglycerol and ceramide formation induced by dopamine D2S receptors via Gbeta gamma -subunits in Balb/c-3T3 cells Am J Physiol Cell Physiol, March 1, 2003; 284(3): C640 - C648. [Abstract] [Full Text] [PDF]

				B. Banihashemi and P. R. Albert Dopamine-D2S Receptor Inhibition of Calcium Influx, Adenylyl Cyclase, and Mitogen-Activated Protein Kinase in Pituitary Cells: Distinct G{alpha} and G{beta}{gamma} Requirements Mol. Endocrinol., October 1, 2002; 16(10): 2393 - 2404. [Abstract] [Full Text] [PDF]

				P. R. Albert G Protein Preferences for Dopamine D2 Inhibition of Prolactin Secretion and DNA Synthesis in GH4 Pituitary Cells Mol. Endocrinol., August 1, 2002; 16(8): 1903 - 1911. [Abstract] [Full Text] [PDF]

				T. A. Jackson, R. E. Schweppe, D. M. Koterwas, and A. P. Bradford Fibroblast Growth Factor Activation of the Rat PRL Promoter is Mediated by PKC{delta} Mol. Endocrinol., September 1, 2001; 15(9): 1517 - 1528. [Abstract] [Full Text] [PDF]

				S. E. Senogles The D2s Dopamine Receptor Stimulates Phospholipase D Activity: A Novel Signaling Pathway for Dopamine Mol. Pharmacol., August 1, 2000; 58(2): 455 - 462. [Abstract] [Full Text]

				M. H. Ghahremani, C. Forget, and P. R. Albert Distinct Roles for Galpha i2 and Gbeta gamma in Signaling to DNA Synthesis and Galpha i3 in Cellular Transformation by Dopamine D2S Receptor Activation in BALB/c 3T3 Cells Mol. Cell. Biol., March 1, 2000; 20(5): 1497 - 1506. [Abstract] [Full Text]

				M. H. Ghahremani, P. Cheng, P. M. C. Lembo, and P. R. Albert Distinct Roles for Galpha i2, Galpha i3, and Gbeta gamma in Modulation of Forskolin- or Gs-mediated cAMP Accumulation and Calcium Mobilization by Dopamine D2S Receptors J. Biol. Chem., April 2, 1999; 274(14): 9238 - 9245. [Abstract] [Full Text] [PDF]

				C. MISSALE, S. R. NASH, S. W. ROBINSON, M. JABER, and M. G. CARON Dopamine Receptors: From Structure to Function Physiol Rev, January 1, 1998; 78(1): 189 - 225. [Abstract] [Full Text] [PDF]

				G. Y. K. Ng, G. Varghese, H. T. Chung, J. Trogadis, P. Seeman, B. F. O'Dowd, and S. R. George Resistance of the Dopamine D2L Receptor to Desensitization Accompanies the Up-Regulation of Receptors on to the Surface of Sf9 Cells Endocrinology, October 1, 1997; 138(10): 4199 - 4206. [Abstract] [Full Text] [PDF]

				W. H. Zhu, L. Conforti, and D. E. Millhorn Expression of dopamine D2 receptor in PC-12 cells and regulation of membrane conductances by dopamine Am J Physiol Cell Physiol, October 1, 1997; 273(4): C1143 - C1150. [Abstract] [Full Text] [PDF]

				V. J. Watts and K. A. Neve Activation of Type II Adenylate Cyclase by D2 and D4 but Not D3 Dopamine Receptors Mol. Pharmacol., August 1, 1997; 52(2): 181 - 186. [Abstract] [Full Text]

				K. N. Furuya, J. V. Thottassery, E. G. Schuetz, M. Sharif, and J. D. Schuetz Bromocriptine Transcriptionally Activates the Multidrug Resistance Gene (pgp2/mdr1b) by a Novel Pathway J. Biol. Chem., April 25, 1997; 272(17): 11518 - 11525. [Abstract] [Full Text] [PDF]

				A. Matsuno, S. Takekoshi, N. Sanno, H. Utsunomiya, Y. Ohsugi, N. Saito, H. Kanemitsu, A. Tamura, T. Nagashima, R. Y. Osamura, et al. Modulation of Protein Kinases and Microtubule-associated Proteins and Changes in Ultrastructure in Female Rat Pituitary Cells: Effects of Estrogen and Bromocriptine J. Histochem. Cytochem., January 1, 1997; 45(6): 805 - 814. [Abstract] [Full Text] [PDF]